<DOC>
	<DOCNO>NCT01532908</DOCNO>
	<brief_summary>The purpose study assess efficacy human monoclonal antibody Hepatitis C ( MBL-HCV1 ) combine telaprevir [ part 1 : HCV protease inhibitor ] sofosbuvir [ part 2 : HCV NS5B polymerase inhibitor ] 56 day treatment duration patient undergo liver transplantation due chronic HCV infection . There option extend study treatment 84 day viral load undetectable day 56 .</brief_summary>
	<brief_title>Open Label Study Efficacy Safety MBL-HCV1 Combination With Oral Direct-Acting Antivirals Patients Undergoing Liver Transplantation Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Patient â‰¥ 18 year age document chronic hepatitis C virus infection genotype 1 undergoing liver transplantation either decease donor living donor . Patient legal guardian/health care proxy must read , understood provide write informed consent HIPAA authorization nature study fully explain . Positive hepatitis B surface Antigen Positive serology HIV Pregnancy Breastfeeding Previous history organ transplant Planned receipt combine organ transplant ( e.g . liver kidney ) Receipt plan receipt immune globulin ( IVIG ) within 90 day enrollment Extrahepatic malignancy currently remission and/or receive systemic chemotherapy and/or radiation within 90 day prior enrollment . Exceptions include chemoembolization hepatocellular carcinoma cutaneous malignancy manage local treatment Hepatocellular carcinoma tumor burden outside Milan criterion Serum creatinine &gt; 2.5 &gt; = six month time enrollment Personal family history ( first degree relative ) deep venous thrombosis pulmonary embolism Receipt liver allograft HCV positive donor Hepatitis B core antibody positive donor Receipt liver allograft donate cardiac death donor Receipt antiviral agent ( licensed investigational ) hepatitis C virus within 90 day prior enrollment , except hepatocellular carcinoma patient treatment sofosbuvir ribavirin detectable HCV RNA within 60 day liver transplantation Previous receipt HCV protease inhibitor ( subject enrol Part 1 : telaprevir ) Receipt investigational study product within 30 day prior enrollment Seizure disorder require anticonvulsant therapy Pulmonary arterial hypertension require sildenafil tadalafil infusion ( subject enrol Part 1 : telaprevir ) Any condition opinion investigator would jeopardize safety right patient participate study make unlikely patient could complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Liver Transplantation</keyword>
</DOC>